Showing 6211-6220 of 7195 results for "".
- UCB: Bimekizumab Shows Joint and Skin Responses in Psoriatic Arthritishttps://practicaldermatology.com/news/ucb-bimekizumab-shows-joint-and-skin-responses-in-psoriatic-arthritis/2457945/UCB has announced that the Phase 2b BE ACTIVE study met the primary objective of establishing dose response for bimekizumab with statistical significance. The study also demonstrated robust efficacy in psor
- Aclaris Initiates Pilot Clinical Trial of ATI-50002 Topical for Vitiligohttps://practicaldermatology.com/news/aclaris-initiates-pilot-clinical-trial-of-ati-50002-topical-for-vitiligo/2457947/Aclaris Therapeutics, Inc., has initiated a Phase 2 open-label clinical trial of ATI-50002, a topical Janus Kinase (JAK) 1/3 inhibitor (ATI-50002 Topical) and an investigational drug, for the potential treatment of non-segmental vitiligo of the face. This trial will evaluate the safety, t
- Biofrontera Files Investigational NDA for Phase 3 Trial of Ameluz for BCChttps://practicaldermatology.com/news/biofrontera-files-investigational-nda-for-phase-3-trial-of-ameluz-for-bcc/2457948/Biofrontera AG has filed an investigational new drug (IND) application with the FDA for its proposed Phase 3 study protocol to evaluate Ameluz® photodynamic therapy (PDT) for the treatment of superficial basal cell carcinoma. The IND filing is in accordance with the advice provided by F
- gel-e Receives US FDA Clearance to Expand its Bandage Product Line for Rx, OTC Usehttps://practicaldermatology.com/news/gel-e-receives-us-fda-clearance-to-expand-its-bandage-product-line-for-rx-otc-use/2457951/The U.S. Food and Drug Administration (FDA) has cleared gel-e Inc.’s adhesive bandage for prescription (Rx) and over-the-counter (OTC) use. This 510(k) clearance expands the Company's label to include the ma
- Harnessing the Power of Social Media: One Viral Post Can Generate Tons of Skin Cancer Awarenesshttps://practicaldermatology.com/news/harnessing-the-power-of-social-media-one-viral-post-can-generate-tons-of-skin-cancer-awareness/2457953/You don’t have to be a celebrity to give voice to a public health concern on social media. Just one person can generate awareness about skin cancer -- when his or her post and picture is shared thousands of times on Facebook, researchers report in the journal Preventive Medicine
- Almirall and Athenex Form Strategic Partnership for Treatment of AKshttps://practicaldermatology.com/news/almirall-and-athenex-form-strategic-partnership-for-treatment-of-aks/2457957/Almirall, S.A and Athenex, Inc. recently formed a partnership to further develop and commercialize KX2-391 for the treatment of actinic keratosis (AK) and other skin conditions. Subject to the terms and conditions of the license agreement, Athenex will grant to Almirall an exclusive
- FDA Warns that Biotin May Interfere with Lab Test Resultshttps://practicaldermatology.com/news/fda-warns-that-biotin-may-interfere-with-lab-test-results/2457961/Biotin may significantly interfere with certain lab tests and cause "clinically significant incorrect lab test results," the US Food and Drug Administration warns. At least 1 death has been related to biotin interference with laboratory results, FDA officials wrote in a Saf
- New Analysis Provides Reassurance on Biosimilar Safetyhttps://practicaldermatology.com/news/new-analysis-provides-reassurance-on-biosimilar-safety/2457964/And they’re … safe. Biosimilars, which have been available in the European Union since 2006, show no substantial differences in the reporting of safety information than their originators, according to a new analysis in the
- Water Baths As Effective As Bleach Baths for Eczemahttps://practicaldermatology.com/news/water-baths-as-effective-as-bleach-baths-for-eczema/2457967/Water baths are as good as bleach baths for treating eczema, and they are safer, finds a new Northwestern Medicine study. Bleach baths can cause stinging and burning of skin, and occasionally even trigger asthma flare-ups in patients. “I don’t know if it throws the bab
- Sonoma Pharmaceuticals Launches Loyonhttps://practicaldermatology.com/news/sonoma-pharmaceuticals-launches-loyon/2457971/Sonoma Pharmaceuticals, Inc. has begun US commercialization of the company’s new Loyon® product. Under the supervision of a healthcare practitioner, Loyon is intended to manage and relieve the scaling, erythema, and itching associated with various types of dermatoses including seborrhea